汎用的な細胞内温度計測を目指した蛍光高分子の合成と褐色脂肪細胞内の熱産生測定への応用

学位の種別: 論文博士審査委員会委員 : （主査）東京大学教授 上田 卓也, 東京大学教授 伊藤 耕一, 東京大学教授 船津 高志, 東京大学准教授 尾山 大明, 東京大学客員准教授 野田 尚宏University of Tokyo(東京大学

ショウトクカン イショウ ノ データベースカ : タテグ ランマ ショウメイ キグ

樟徳館は、記念館とともに樟蔭学園の歴史的遺産ともいえる登録有形文化財に指定されている建築物である。この貴重な文化遺産を未来に引き継いでいくために、その維持・保全にかかわる研究が今後必要であると考える。本研究は、まず今後の樟徳館調査のための基本となる建物平面図、展開図などのデータベースを作成する。さらに、樟徳館の床・壁・天井の意匠とその材料、また建具・欄間の意匠とその材質、照明器具の意匠、材質など、それぞれのデータベースを作成するものである。データベースは、各項目につきそれぞれの設置場所、意匠寸法、材質、数量などをまとめている

Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER)

BackgroundAlternate-day administration of S-1 is thought to reduce toxicities. This phase II study evaluated S-1 on alternate days combined with bevacizumab as first-line treatment for elderly patients with metastatic colorectal cancer.Patients and methodsEligible patients had histologically proven colorectal adenocarcinoma, measurable metastatic lesions, age ≥ 75 years, Eastern Cooperative Oncology Group performance status ≤ 1, no previous chemotherapy, and refused oxaliplatin- or irinotecan-containing regimens. Patients received 40 mg, 50 mg, or 60 mg (body surface area ≤ 1.25 m2, > 1.25 to ≤ 1.50 m2, or > 1.50 m2, respectively) of S-1 twice orally on Sunday, Monday, Wednesday, and Friday every week. Bevacizumab (7.5 mg/kg) was administered every 3 weeks. The primary endpoint was progression-free survival.ResultsOf 54 enrolled patients, 50 patients were evaluated for efficacy and 53 for safety. The median age was 79 years (range 75–88 years). The median progression-free survival was 8.1 months (95% confidence interval (CI) 6.7–9.5 months). The median overall survival was 23.1 months (95% CI 17.4–28.8 months). The response rate was 44% (95% CI 30.2–57.8%), and the disease control rate was 88% (95% CI 79.0–97.0%). Grade 3 or higher hematologic, non-hematologic, and bevacizumab-related adverse events occurred in 9%, 11%, and 25% of patients, respectively. The most common grade 3 and 4 treatment-related adverse events were hypertension (11%), nausea (6%), fatigue (6%), anemia (6%), and proteinuria (6%). Only 6 patients discontinued treatment due to adverse events.ConclusionS-1 on alternate days combined with bevacizumab showed better tolerability and comparable survival compared with the results of similar studies